Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
View in:
PubMed
subject areas
Aged
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Capecitabine
Colorectal Neoplasms
Cost-Benefit Analysis
Disease Progression
Drug Costs
Female
Humans
Maintenance Chemotherapy
Male
Markov Chains
Medicare
Middle Aged
Models, Economic
Neoplasm Metastasis
Quality of Life
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic
Time Factors
Treatment Outcome
United States
authors with profiles
Blase Polite